3//SEC Filing
OrbiMed Capital GP VI LLC 3
Accession 0000947871-20-000207
CIK 0000891293other
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 5:05 PM ET
Size
9.0 KB
Accession
0000947871-20-000207
Insider Transaction Report
Form 3
ORBIMED ADVISORS LLC
10% Owner
Holdings
- 9,520,000(indirect: See footnotes)
Common Stock
- (indirect: See footnotes)
Series X Preferred Stock
→ Common Stock (2,980,000 underlying)
OrbiMed Capital GP VI LLC
10% Owner
Holdings
- 9,520,000(indirect: See footnotes)
Common Stock
- (indirect: See footnotes)
Series X Preferred Stock
→ Common Stock (2,980,000 underlying)
Footnotes (4)
- [F1]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPI VI.
- [F2]This report on Form 3 is jointly filed by GP VI and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]Each share of the Series X Preferred Stock (the "Preferred Stock') is convertible into 10,000 shares of common stock of the Issuer ("Common Stock") at the election of the holder; provided that, the holder will be prohibited from exercising the Preferred Stock for shares of Common Stock if, as a result of such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding.
- [F4]The Preferred Stock has no expiration date.
Documents
Issuer
CTI BIOPHARMA CORP
CIK 0000891293
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001682115
Filing Metadata
- Form type
- 3
- Filed
- Mar 9, 8:00 PM ET
- Accepted
- Mar 10, 5:05 PM ET
- Size
- 9.0 KB